scholarly journals A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci

Vaccine ◽  
2021 ◽  
Author(s):  
Rika Nakahashi-Ouchida ◽  
Yohei Uchida ◽  
Yoshikazu Yuki ◽  
Yuko Katakai ◽  
Tomoyuki Yamanoue ◽  
...  
Keyword(s):  
Nasal Vaccine

scholarly journals Nasal Immunization with Porphyromonas gingivalis Outer Membrane Protein Decreases P. gingivalis-Induced Atherosclerosis and Inflammation in Spontaneously Hyperlipidemic Mice

2008 ◽  
Vol 76 (7) ◽  
pp. 2958-2965 ◽  
Author(s):  
Y. Koizumi ◽  
T. Kurita-Ochiai ◽  
S. Oguchi ◽  
M. Yamamoto
Keyword(s):  
Membrane Protein ◽  
Outer Membrane ◽  
Porphyromonas Gingivalis ◽  
Atherosclerotic Plaque ◽  
Outer Membrane Protein ◽  
Serum Levels ◽  
Aortic Sinus ◽  
Cytokines And Chemokines ◽  
Nasal Vaccine ◽  
Nasal Immunization

ABSTRACT Porphyromonas gingivalis has been shown to accelerate atherosclerotic lesion development in hyperlipidemic animals. We assessed the potential of a nasal vaccine against P. gingivalis infection for the prevention of atherosclerosis. Apolipoprotein E-deficient spontaneously hyperlipidemic (Apoeshl) mice were nasally immunized with the 40-kDa outer membrane protein (OMP) of P. gingivalis plus cholera toxin (CT) as adjuvant and then challenged intravenously with P. gingivalis strain 381. The animals were euthanized 11 or 14 weeks later. Atheromatous lesions in the proximal aorta of each animal were analyzed histomorphometrically, and the serum concentrations of 40-kDa OMP-specific antibodies and cytokines were determined. The areas of the aortic sinus that were covered with atherosclerotic plaque and the serum levels of inflammatory cytokines and chemokines were increased in Apoeshl mice challenged with P. gingivalis compared to nonchallenged mice. In comparison, nasal immunization with 40-kDa OMP plus CT significantly reduced atherosclerotic plaque accumulation in the aortic sinus and lowered the serum levels of cytokines and chemokines compared to nonimmunized animals. Nasal immunization also induced 40-kDa OMP-specific serum immunoglobulin G (IgG) and saliva IgA antibody responses. These findings suggest that systemic infection with P. gingivalis accelerates atherosclerosis in Apoeshl mice, and 40-kDa OMP plus CT may be an effective nasal vaccine for the reduction of atherosclerosis accelerated by P. gingivalis in the hyperlipidemic mouse model.

Research Spotlight: Thermal-sensitive hydrogels as nasal vaccine delivery systems

2012 ◽  
Vol 3 (10) ◽  
pp. 1151-1153
Author(s):  
Jie Wu ◽  
You-Bin Wu ◽  
Dong-Xia Hao ◽  
Meng Zhou ◽  
Qing-Zhe Fan ◽  
...  
Keyword(s):  
Vaccine Delivery ◽  
Delivery Systems ◽  
Nasal Vaccine ◽  
Nasal Vaccine Delivery

scholarly journals Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice

2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Rui Tada ◽  
Shoko Muto ◽  
Tomoko Iwata ◽  
Akira Hidaka ◽  
Hiroshi Kiyono ◽  
...  
Keyword(s):  
Immune Responses ◽  
Cpg Odn ◽  
Class B ◽  
Nasal Vaccine

scholarly journals α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor

2005 ◽  
Vol 175 (5) ◽  
pp. 3309-3317 ◽  
Author(s):  
Sung-Youl Ko ◽  
Hyun-Jeong Ko ◽  
Woo-Sung Chang ◽  
Se-Ho Park ◽  
Mi-Na Kweon ◽  
...  
Keyword(s):  
Immune Responses ◽  
Viral Infection ◽  
Vaccine Adjuvant ◽  
Nasal Vaccine

PEG-PLA Nanoparticles as Carriers for Nasal Vaccine Delivery

2004 ◽  
Vol 17 (2) ◽  
pp. 174-185 ◽  
Author(s):  
A. Vila ◽  
A. Sánchez ◽  
C. Évora ◽  
I. Soriano ◽  
J.L. Vila Jato ◽  
...  
Keyword(s):  
Vaccine Delivery ◽  
Nasal Vaccine ◽  
Nasal Vaccine Delivery

scholarly journals Mucosal vaccines: wisdom from now and then

2021 ◽  
Author(s):  
Hiroshi Kiyono ◽  
Yoshikazu Yuki ◽  
Rika Nakahashi-Ouchida ◽  
Kohtaro Fujihashi
Keyword(s):  
Immune System ◽  
Infectious Diseases ◽  
Driving Forces ◽  
Oral Vaccine ◽  
Agricultural Science ◽  
Mucosal Immunology ◽  
Mucosal Immune System ◽  
Novel Approach ◽  
Nasal Vaccine ◽  
Mucosal Vaccines

Abstract The oral and nasal cavities are covered by the mucosal epithelium that starts at the beginning of the aero-digestive tract. These mucosal surfaces are continuously exposed to environmental antigens including pathogens and allergens and are thus equipped with a mucosal immune system that mediates initial recognition of pathogenicity and initiates pathogen-specific immune responses. At the dawn of our scientific effort to explore the mucosal immune system, dental science was one of the major driving forces as it provided insights into the importance of mucosal immunity and its application for the control of oral infectious diseases. The development of mucosal vaccines for the prevention of dental caries was thus part of a novel approach that contributed to building the scientific foundations of the mucosal immune system. Since then, mucosal immunology and vaccines have gone on a scientific journey to become one of the major entities within the discipline of immunology. Here, we introduce our past and current efforts and future directions for the development of mucosal vaccines, specifically a rice-based oral vaccine (MucoRice) and a nanogel-based nasal vaccine, with the aim of preventing and controlling gastrointestinal and respiratory infectious diseases using the interdisciplinary fusion of mucosal immunology with agricultural science and biomaterial engineering, respectively.

scholarly journals Riboflavin as a Mucosal Adjuvant for Nasal Influenza Vaccine

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1296
Author(s):  
Yinyan Yin ◽  
Jinyuan Wang ◽  
Xing Xu ◽  
Bangyue Zhou ◽  
Sujuan Chen ◽  
...  
Keyword(s):  
Low Cost ◽  
Mapk Signaling ◽  
Mitogen Activated Protein Kinase ◽  
Secretory Iga ◽  
Mucosal Adjuvant ◽  
Intranasal Immunization ◽  
Mitogen Activated Protein ◽  
Nasal Vaccine ◽  
Living Organisms ◽  
Cellular Immune

Intranasal immunization with whole inactivated virus (WIV) is an important strategy used for influenza prevention and control. However, a powerful mucosal adjuvant is required to improve nasal vaccine efficacy. Riboflavin, as a food additive with the advantages of being safe and low-cost, widely exists in living organisms. In this paper, the mucosal adjuvant function of riboflavin was studied. After intranasal immunization with H1N1 WIV plus riboflavin in mice, we found that the mucosal immunity based on the secretory IgA (sIgA) levels in the nasal cavity, trachea, and lung were strongly enhanced compared with H1N1 WIV alone. Meanwhile, the IgG, IgG1, and IgG2a levels in serum also showed a high upregulation and a decreased ratio of IgG1/IgG2a, which implied a bias in the cellular immune response. Moreover, riboflavin strongly improved the protection level of H1N1 inactivated vaccine from a lethal influenza challenge. Furthermore, riboflavin was found to possess the capacity to induce dendritic cell (DC) phenotypic (MHCII, CD40, CD80, and CD86) and functional maturation, including cytokine secretion (TNF-α, IL-1β, IL-12p70, and IL-10) and the proliferation of allogeneic T cells. Lastly, we found that the DC maturation induced by riboflavin was dependent on the activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which plays an important role in immune regulation. Therefore, riboflavin is expected to be developed as an alternative mucosal adjuvant for influenza nasal vaccine application.

Sign in / Sign up

Export Citation Format

Share Document